These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8876037)

  • 1. Structure-affinity studies of C-terminally modified analogs of neuropeptide Y led to a novel class of peptidic Y1 receptor antagonist.
    Hoffmann S; Rist B; Videnov G; Jung G; Beck-Sickinger AG
    Regul Pept; 1996 Aug; 65(1):61-70. PubMed ID: 8876037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand binding and functional effects of systematic double D-amino acid residue substituted neuropeptide Y analogs on Y1 and Y2 receptor types.
    Grundemar L; Kahl U; Callréus T; Langel U; Bienert M; Beyermann M
    Regul Pept; 1996 Apr; 62(2-3):131-6. PubMed ID: 8795076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions.
    Kirby DA; Boublik JH; Rivier JE
    J Med Chem; 1993 Nov; 36(24):3802-8. PubMed ID: 8254609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations.
    Beck-Sickinger AG; Wieland HA; Wittneben H; Willim KD; Rudolf K; Jung G
    Eur J Biochem; 1994 Nov; 225(3):947-58. PubMed ID: 7957231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor.
    Sautel M; Rudolf K; Wittneben H; Herzog H; Martinez R; Munoz M; Eberlein W; Engel W; Walker P; Beck-Sickinger AG
    Mol Pharmacol; 1996 Aug; 50(2):285-92. PubMed ID: 8700135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational and biological studies of neuropeptide Y analogs containing structural alterations.
    Fournier A; Gagnon D; Quirion R; Cadieux A; Dumont Y; Pheng LH; St-Pierre S
    Mol Pharmacol; 1994 Jan; 45(1):93-101. PubMed ID: 8302286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors.
    Beck-Sickinger AG; Jung G
    Biopolymers; 1995; 37(2):123-42. PubMed ID: 7893945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of chimeric NPY/galanin peptides M32 and M242 to cloned neuropeptide Y receptor subtypes Y1, Y2, Y4, and Y5.
    Berglund MM; Saar K; Lundell I; Langel U; Larhammar D
    Neuropeptides; 2001; 35(3-4):148-53. PubMed ID: 11884204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors.
    Grandt D; Schimiczek M; Rascher W; Feth F; Shively J; Lee TD; Davis MT; Reeve JR; Michel MC
    Regul Pept; 1996 Nov; 67(1):33-7. PubMed ID: 8952003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonistic properties of centrally truncated analogs of [D-Trp(32)]NPY.
    Balasubramaniam A; Ujhelyi M; Borchers M; Huang Y; Zhai W; Zhou Y; Johnson M; Sheriff S; Fischer JE
    J Med Chem; 1996 Mar; 39(5):1142-7. PubMed ID: 8676351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues.
    Kirby DA; Koerber SC; Craig AG; Feinstein RD; Delmas L; Brown MR; Rivier JE
    J Med Chem; 1993 Feb; 36(3):385-93. PubMed ID: 8426366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Y1 and Y2 receptor selective neuropeptide Y analogues: evidence for a Y1 receptor subclass.
    Kirby DA; Koerber SC; May JM; Hagaman C; Cullen MJ; Pelleymounter MA; Rivier JE
    J Med Chem; 1995 Oct; 38(22):4579-86. PubMed ID: 7473586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of neuropeptide Y1 and neuropeptide Y2 receptors by substituted and truncated neuropeptide Y analogs: identification of signal epitopes.
    Grundemar L; Krstenansky JL; Håkanson R
    Eur J Pharmacol; 1993 Mar; 232(2-3):271-8. PubMed ID: 8467862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Truncated, branched, and/or cyclic analogues of neuropeptide Y: importance of the pancreatic peptide fold in the design of specific Y2 receptor ligands.
    Reymond MT; Delmas L; Koerber SC; Brown MR; Rivier JE
    J Med Chem; 1992 Oct; 35(20):3653-9. PubMed ID: 1433176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-terminal modifications of neuropeptide Y and its analogs leading to selectivity for the mouse brain receptor over the porcine spleen receptor.
    Krstenansky JL; Owen TJ; Payne MH; Shatzer SA; Buck SH
    Neuropeptides; 1990 Nov; 17(3):117-20. PubMed ID: 1964720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
    Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
    Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.
    Michel MC; Gaida W; Beck-Sickinger AG; Wieland HA; Doods H; Dürr H; Jung G; Schnorrenberg G
    Mol Pharmacol; 1992 Oct; 42(4):642-8. PubMed ID: 1331755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solution structure by 2D 1H-NMR of a chimeric peptide recognized by galanin and neuropeptide Y receptors.
    Arvidsson K; Land T; Langel U; Bartfai T; Ehrenberg A
    Biochemistry; 1993 Aug; 32(30):7787-98. PubMed ID: 7688568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NPY Y1 antagonists: structure-activity relationships of arginine derivatives and hybrid compounds with arpromidine-like partial structures.
    Aiglstorfer I; Uffrecht A; Gessele K; Moser C; Schuster A; Merz S; Malawska B; Bernhardt G; Dove S; Buschauer A
    Regul Pept; 1998 Sep; 75-76():9-21. PubMed ID: 9802389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships with neuropeptide Y analogues: a comparison of human Y1-, Y2- and rat Y2-like systems.
    Cox HM; Tough IR; Ingenhoven N; Beck-Sickinger AG
    Regul Pept; 1998 Sep; 75-76():3-8. PubMed ID: 9802388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.